Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372628
For the License, Licensor grants a worldwide license under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products, solely within the Field of Use.
For the Right to Grant Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products within the Field of Use.
Platelet-Derived Growth Factor Compositions and Methods of Use Thereof;
Maxillofacial Bone Augmentation Using rhPDGF-BB and a Biocompatible Matrix;
Compositions and Methods for Repairing Cartilage Defects;
Compositions and Methods for Treating Bone;
Prevention and Treatment for Osteonecrosis and Osteonecrosis of the Jaw;
Methods and Compositions for Treating the Vertebral Column; and,
Compositions and Methods for Treating Rotator Cuff Injuries.
Licensor has certain assets related to the orofacial therapeutic business.
rhPDGF means recombinant human platelet derived growth factor.
Licensed Products means any product with application within the Field of Use that Licensor and/or Licensee develops or has developed which is covered by the Licensed Technology, developed through the use of a process which is covered by the Licensed Technology, or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Technology, including, but not limited to
— any Growth Factor product, including GEM 21S, GEM ONJ, GEM 22A, and a GEM OS2-like product for application within the Field of Use, including Growth Factors alone, combinations of Growth Factors, and combinations of Growth Factors with non-Growth Factor products, and any component thereof, for which commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement;
— any device, e.g., bone matrix material, implant and/or related product, for which the commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement.
IPSCIO Record ID: 372627
Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.
For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.
Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.
GEM 21SÂ® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.
GEM 21SÂ® growth-factor enhanced matrix combines a bioactive protein â€“ highly purified rhPDGF-BB â€“ with an osteoconductive matrix, ÃŸ-TCP.
GEM 21SÂ® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.
This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.
The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranioâ€¢ maxillofacial osseous defects.
The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.
IPSCIO Record ID: 58867
Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets.